Objective
The NEOTREG project is an SME-led, multidisciplinary initiative designed to accelerate the clinical translation of EGL-001, a first-in-class bispecific fusion antibody that selectively depletes regulatory T cells (Tregs) within the tumour microenvironment. By overcoming immune suppression, EGL-001 enhances the the efficacy of immune checkpoint inhibitors and address a major resistance mechanism in solid tumours. The project will conduct a multicentre, randomised, open-label Phase I/II neoadjuvant clinical trial in patients with head and neck squamous cell carcinoma (HNSCC), a high-incidence, high-mortality cancer with limited benefit from current immunotherapies.
Beyond evaluating safety, tolerability, and early efficacy of EGL-001 in combination with pembrolizumab, NEOTREG integrates a comprehensive translational research programme including multi-omics profiling, immune monitoring, and AI-driven pathomics modelling. This will deliver predictive biomarkers for patient stratification and future companion diagnostics, supporting regulatory alignment and de-risking later-stage development.
The consortium unites Egle Therapeutics (France), University College London (UK), Vall d’Hebron Institute of Oncology (Spain), Gustave Roussy (France), and Technical University of Dresden (Germany). Together, they provide cutting-edge expertise in immunology, genomics, pathology, and computational biology, alongside established clinical trial capacity across EU Member States.
By delivering robust first-in-human efficacy data, novel biomarkers, and a scalable translational framework, NEOTREG not only advances EGL-001 but also creates a reproducible model for SME-driven translation of innovative biotech therapies in Europe. The project directly addresses the call’s goals by supporting the transition from preclinical to early clinical development, strengthening Europe’s competitiveness in biotechnology, and anchoring exploitation in the EU through a robust commercialisation strategy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences genetics
- medical and health sciences clinical medicine oncology skin cancer squamous cell carcinoma
- medical and health sciences basic medicine pathology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.2.1 - Health
MAIN PROGRAMME
See all projects funded under this programme -
HORIZON.2.1.5 - Tools, Technologies and Digital Solutions for Health and Care, including personalised medicine
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-RIA - HORIZON Research and Innovation Actions
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-HLTH-2025-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
92150 SURESNES
France
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.